{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "76-year-old man admitted to hospital with cough for several months. History of smoking 20 cigarettes per day for >30 years, quit 2 years prior. No family history of genetic disease or tumor. Routine blood, fecal, and urine tests normal.",
        "clinical_data": {
          "social_history": [
            {
              "category": "smoking",
              "status": "past",
              "description": "20 cigarettes per day for >30 years, quit 2 years prior"
            }
          ],
          "HPI": [
            {
              "summary": "cough for several months",
              "duration": "several months"
            }
          ]
        }
      }
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "Comprehensive evaluations of cardiac, hepatic, renal, pulmonary, coagulation, and electrolyte functions showed no significant abnormalities. Tumor markers, including CEA, Cyfra21-1, and SCC, were within normal ranges. Physical examination indicated a Karnofsky Performance Status (KPS) of 80%, with less than 5% weight loss over three months. Contrasted CT scan revealed a 5cm x 3cm mass in the lower lobe of the right lung with uneven enhancement.",
        "clinical_data": {
          "vitals": [
            {
              "type": "Karnofsky Performance Status",
              "value": "80",
              "unit": "%"
            },
            {
              "type": "Weight loss",
              "value": "5",
              "unit": "%",
              "duration": "3 months"
            }
          ],
          "imaging": [
            {
              "type": "Mass",
              "body_part": "Lower lobe of the right lung",
              "modality": "CT",
              "finding": "5cm x 3cm mass with uneven enhancement"
            }
          ]
        }
      }
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 2,
        "content": "PET/CT and cranial MRI showed no distant metastasis. No mediastinal lymph node enlargement.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Positron emission tomography",
              "body_part": "entire body",
              "modality": "PET",
              "finding": "no distant metastasis",
              "date": null
            },
            {
              "type": "Computed tomography",
              "body_part": "entire body",
              "modality": "CT",
              "finding": "no distant metastasis",
              "date": null
            },
            {
              "type": "Magnetic resonance imaging",
              "body_part": "cranium",
              "modality": "MRI",
              "finding": "no distant metastasis",
              "date": null
            },
            {
              "type": "Lymph node examination",
              "body_part": "mediastinum",
              "modality": null,
              "finding": "no mediastinal lymph node enlargement",
              "date": null
            }
          ]
        }
      }
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 3,
        "content": "Biopsy showed LUSC (Lung Squamous Cell Carcinoma). Clinical staging T2bN0M0 IIA.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C0007132",
              "label": "Squamous cell carcinoma of lung",
              "status": "active"
            }
          ],
          "imaging": [
            {
              "type": "imaging",
              "body_part": "lung",
              "modality": "Biopsy",
              "finding": "Lung Squamous Cell Carcinoma",
              "impression": "Lung Squamous Cell Carcinoma"
            }
          ]
        }
      }
    },
    {
      "id": "N5",
      "label": "Step 5",
      "customData": {
        "node_id": "E",
        "node_step_index": 4,
        "content": "Patient and family refused surgery, radiotherapy, chemotherapy and immune checkpoint inhibitor treatment.",
        "clinical_data": {}
      }
    },
    {
      "id": "N6",
      "label": "Step 6",
      "customData": {
        "node_id": "F",
        "node_step_index": 5,
        "content": "NGS analysis revealed FGFR3-IER5L fusion mutation (MAF 12.5%), NF1 shift mutation (MAF=13.4%), TP53 nonsense mutation (MAF=11.1%), CSF1R splicing mutation (MAF=13.7%) and ROS1 exon 34 missense mutation (MAF=15.4%). Tumor mutation burden (TMB) of 5.3 mut/Mb and microsatellite stability (MSS).",
        "clinical_data": {
          "labs": [
            {
              "test": "Tumor mutation burden",
              "value": "5.3",
              "unit": "mut/Mb"
            },
            {
              "test": "Microsatellite stability",
              "value": "MSS"
            }
          ],
          "diagnoses": [
            {
              "code": "FGFR3-IER5L fusion mutation",
              "label": "FGFR3-IER5L fusion mutation",
              "status": "active"
            },
            {
              "code": "NF1 shift mutation",
              "label": "NF1 shift mutation",
              "status": "active"
            },
            {
              "code": "TP53 nonsense mutation",
              "label": "TP53 nonsense mutation",
              "status": "active"
            },
            {
              "code": "CSF1R splicing mutation",
              "label": "CSF1R splicing mutation",
              "status": "active"
            },
            {
              "code": "ROS1 exon 34 missense mutation",
              "label": "ROS1 exon 34 missense mutation",
              "status": "active"
            }
          ]
        }
      }
    },
    {
      "id": "N7",
      "label": "Step 7",
      "customData": {
        "node_id": "G",
        "node_step_index": 6,
        "content": "Patient showed a partial response to anlotinib single agent treatment.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C1697479",
              "indication": "Neoplasm (disease)",
              "status": "active"
            }
          ]
        }
      }
    },
    {
      "id": "N8",
      "label": "Step 8",
      "customData": {
        "node_id": "H",
        "node_step_index": 7,
        "content": "PD-L1 TPS was 3% detected by 22C3 antibody.",
        "clinical_data": {
          "labs": [
            {
              "test": "PD-L1 Tumor Proportion Score",
              "value": "3%",
              "unit": "%",
              "flag": "unknown"
            }
          ]
        }
      }
    },
    {
      "id": "N9",
      "label": "Step 9",
      "customData": {
        "node_id": "I",
        "node_step_index": 8,
        "content": "Patient declined treatment with FGFR inhibitors and was administered anlotinib 12 mg p.o. every morning (days 1-14, with a 21-day cycle).",
        "clinical_data": {
          "medications": [
            {
              "drug": "Anlotinib",
              "dosage": "12 mg",
              "frequency": "every morning",
              "modality": "oral",
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ]
        }
      }
    },
    {
      "id": "N10",
      "label": "Step 10",
      "customData": {
        "node_id": "J",
        "node_step_index": 9,
        "content": "After anlotinib treatment for 2 cycles, the patient achieved a partial response",
        "clinical_data": {
          "procedures": [
            {
              "name": "Anlotinib treatment",
              "outcome": "Partial response"
            }
          ]
        }
      }
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Initial presentation and workup. Comprehensive evaluations of cardiac, hepatic, renal, pulmonary, coagulation, and electrolyte functions showed no significant abnormalities. Tumor markers, including CEA, Cyfra21-1, and SCC, were within normal ranges. Physical examination indicated a Karnofsky Performance Status (KPS) of 80%, with less than 5% weight loss over three months. Contrasted CT scan revealed a 5cm x 3cm mass in the lower lobe of the right lung with uneven enhancement."
      }
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Further imaging to assess for metastasis. PET/CT and cranial MRI showed no distant metastasis. No mediastinal lymph node enlargement."
      }
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "Biopsy performed to determine cancer type. Biopsy showed LUSC (Lung Squamous Cell Carcinoma). Clinical staging T2bN0M0 IIA.",
        "transition_event": {
          "trigger_type": "procedure",
          "trigger_entities": [
            "C0005767"
          ],
          "change_type": "addition",
          "target_domain": "diagnosis"
        }
      }
    },
    {
      "from": "N4",
      "to": "N5",
      "data": {
        "edge_id": "D_to_E",
        "branch_flag": true,
        "content": "Patient declined standard treatment options. Patient and family refused surgery, radiotherapy, chemotherapy and immune checkpoint inhibitor treatment."
      }
    },
    {
      "from": "N5",
      "to": "N6",
      "data": {
        "edge_id": "E_to_F",
        "branch_flag": true,
        "content": "NGS analysis performed to identify potential targetable mutations. NGS analysis revealed FGFR3-IER5L fusion mutation (MAF 12.5%), NF1 shift mutation (MAF=13.4%), TP53 nonsense mutation (MAF=11.1%), CSF1R splicing mutation (MAF=13.7%) and ROS1 exon 34 missense mutation (MAF=15.4%). Tumor mutation burden (TMB) of 5.3 mut/Mb and microsatellite stability (MSS)."
      }
    },
    {
      "from": "N6",
      "to": "N7",
      "data": {
        "edge_id": "F_to_G",
        "branch_flag": true,
        "content": "Patient showed a partial response to anlotinib single agent treatment."
      }
    },
    {
      "from": "N7",
      "to": "N8",
      "data": {
        "edge_id": "G_to_H",
        "branch_flag": true,
        "content": "PD-L1 testing performed. PD-L1 TPS was 3% detected by 22C3 antibody."
      }
    },
    {
      "from": "N8",
      "to": "N9",
      "data": {
        "edge_id": "H_to_I",
        "branch_flag": true,
        "content": "Treatment decision and medication administration. Patient declined treatment with FGFR inhibitors and was administered anlotinib 12 mg p.o. every morning (days 1-14, with a 21-day cycle).",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C1697479"
          ],
          "change_type": "addition",
          "target_domain": "medication"
        }
      }
    },
    {
      "from": "N9",
      "to": "N10",
      "data": {
        "edge_id": "I_to_J",
        "branch_flag": true,
        "content": "Treatment response after 2 cycles of anlotinib. After anlotinib treatment for 2 cycles, the patient achieved a partial response",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C1697479"
          ],
          "change_type": "other",
          "target_domain": "diagnosis"
        }
      }
    }
  ]
}